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Tobacco carcinogens induce DNA adducts that are repairedby the nucleotide excision repair (NER) pathway.1 In-
haled combustion-derived particles, such as cigarette smoke,
cause a local pulmonary inflammatory response that is char-
acterized by the influx of neutrophils into the airways. On
entering the lung, neutrophils are activated and release reac-
tive oxygen species and an array of proteins, such as myelo-
peroxidase. A significant reduction of NER in human alveolar
epithelial cells was observed when they were cocultured with
activated neutrophils.2
NER, a highly versatile pathway for DNA damage
removal, is often dysfunctional in non-small cell lung cancer
(NSCLC) and could, therefore, be the Achilles heel for
customizing chemotherapy. NER removes numerous types of
DNA helix-distorting lesions, including cisplatin- and ultra-
violet-induced photo products.1 Inherited defects in the NER
process cause serious repair disorders: xeroderma pigmento-
sum (XP), with extreme risk of ultraviolet-induced skin
cancer, and Cockayne syndrome. NER functions by a “cut-
and-paste” mechanism in which cisplatin damage recogni-
tion, local opening of the DNA helix around the lesion,
damage excision, and gap filling occur in successive steps1,3–5
(Figure 1). NER is composed of two subpathways: global
genome NER (GG-NER) and transcription-coupled NER
(TC-NER), which share the same core mechanism but differ
in the way lesions are recognized.6 NER-defective XP is
classified into seven complementation groups, XPA to XPG.
XPC and XPE are specifically defective in GG-NER, which
repairs the damage on the nontranscribed strand, whereas the
other XP groups involve deficiencies in both TC-NER and
GG-NER.7
The first step in GG-NER is damage recognition by the
heterodimer XPC/hHR23B, which binds with higher affinity
to helix-distorting DNA lesions than to nondamaged, double-
stranded DNA1 (Figure 1A). Various NER factors, including
transcription factor IIH (TFIIH, a general transcription factor
for RNA polymerase II), XPA, replication protein A (RPA),
and XPG work together to repair DNA damage (Figure 1B).
TFIIH can be divided into two subcomplexes: the core TFIIH
(composed of XPB, p62, p52, p44, p34, and p8) and a
cdk-activating kinase subcomplex (containing cdk7, cyclin H,
and MAT1).7 Both subcomplexes are bridged by XPD. In
NER, TFIIH unwinds the duplex DNA around the lesion to
allow the recruitment of the NER factors XPA, RPA, XPG,
and excision repair cross-complementing 1 (ERCC1)/XPF
(Figure 1B). TFIIH, with the two helicases XPB and XPD,
opens an approximately 30-base-long DNA segment around
the platinum damage. This open intermediate is stabilized by
RPA and XPA (Figure 1C). The DNA strand that contains the
damaged base(s) is excised by the two NER endonucleases
XPG and ERCC1/XPF (Figure 1D). XPG cleaves the dam-
aged DNA strand 3= from the lesion, and ERCC1/XPF
cleaves the damaged strand 5= from the lesion (Figure 1D).
The resulting gap is filled by DNA polymerase  or  in the
presence of replication factors8 (Figure 1E). Importantly, the
ERCC1/XPF structure-specific nuclease has an additional
role in the repair of cisplatin adducts besides its function in
NER: the recombination repair of interstrand cross-links.9
Moreover, colocalization of ERCC1 foci and RAD51 foci in
response to cisplatin treatment has recently been found and
may represent recruitment of ERCC1/XPF to sites of recom-
bination repair.10 Nevertheless, in addition to NER, cisplatin-
induced cytotoxicity requires the interaction of components
from several different DNA damage-processing systems.11
CLINICAL STUDIES TESTING PLATINUM
OUTCOME ACCORDING TO ERCC1, RRM1,
AND BRCA1
In recent years, ERCC1 and other components of DNA
damage-processing systems have been examined in the clin-
ical setting (Figure 2). High tumor tissue levels of ERCC1
mRNA in ovarian and gastric cancer patients have been associ-
ated with cisplatin resistance.12,13 When intratumoral ERCC1
mRNA derived from paraffin-embedded tumor specimens was
measured by real-time reverse transcriptase polymerase chain
reaction in metastatic colon cancer patients treated with oxali-
platin and 5-fluorouracil, high levels of ERCC1 significantly
correlated with poor response and shorter survival.14
Several studies in stage IV gemcitabine/cisplatin-
treated NSCLC show that patients with low ERCC1 or
ribonucleotide reductase subunit M1 (RRM1) mRNA levels
have a median survival of 15 months. Nevertheless, the
predictive value of low ERCC1 mRNA levels found in our
original study15 was not borne out by our second study with
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Italian patients, in which low ERCC1 levels showed a non-
significant trend toward better survival (unpublished data).
Conversely, in these same Italian patients, low RRM1
mRNA levels were significantly associated with improved
survival (15.5 versus 6.8 months; p  0.002).16 No differ-
ences were found according to RRM1 status in patients
treated with paclitaxel/carboplatin or vinorelbine/cisplatin
as part of the original phase III randomized trial.17
Whereas no differences between the three different cispla-
tin doublets were found in the original trial, RRM1 iden-
tified patients with better survival in the gemcitabine/
cisplatin-treated arm, which can be attributed to the effect
of RRM1 on gemcitabine metabolism and on the NER
pathway. Low RRM1 levels were associated with a signif-
icantly better survival18 in NSCLC patients treated with
gemcitabine/cisplatin as part of a large phase III random-
ized trial.19 Nevertheless, the predictive value of RRM1
was not evident in the group of patients who received
gemcitabine/cisplatin/vinorelbine triplets, raising the hy-
pothesis that antimicrotubule drugs act on the NER path-
way in a different way, as explained below. In another
study20 of patients treated with neoadjuvant gemcitabine/
cisplatin and then surgery, the lowest RRM1 mRNA levels
(bottom quartile) predicted significantly better survival in
comparison with those with higher levels of RRM1, whereas
no differences were observed according to ERCC1 or XPD
mRNA levels.
The predictive role of ERCC1 in cisplatin response was
tested in a customized chemotherapy trial based on tumor
ERCC1 mRNA levels. Patients in the control arm received
docetaxel plus cisplatin. Patients in the customized arm
received treatment based on ERCC1 mRNA levels: those
with low levels received docetaxel plus cisplatin, and those
with high levels received non–cisplatin-based treatment (do-
cetaxel plus gemcitabine). Objective response was observed
in 53 patients (39.3%) in the control arm and 107 patients
(50.7%) in the customized arm (p  0.019).21 This study
shows that assessment of ERCC1 mRNA expression in pa-
tient tumor tissue is feasible in the clinical setting and
predicts response to docetaxel plus cisplatin. Nevertheless,
the response benefit did not translate into improved survival,
which can be partly explained by the fact that antimicrotubule
drugs may not be the best partner for cisplatin in the presence
of low ERCC1 levels. The combination of ERCC1 and
RRM1 gene expression levels in frozen tumor specimens has
also been used to select chemotherapy22: patients with low
levels of both genes received carboplatin plus gemcitabine;
those with high levels of both genes received docetaxel plus
vinorelbine; those with high ERCC1 but low RRM1 received
gemcitabine plus docetaxel; and those with low ERCC1 and
high RRM1 received docetaxel plus carboplatin. This study
confirmed the feasibility of this approach and paved the way
for additional studies.
GG-NER might not correctly detect cisplatin DNA
adducts, because it has been shown to possess a low affinity
for these adducts.23,24 On the other hand, defects in TC-NER
(Figure 1) render cells markedly hypersensitive to cisplatin.8
Unlike ERCC1, breast cancer susceptibility gene 1 (BRCA1)
is involved in TC-NER,25,26 and BRCA1-deficient cells are
hypersensitive to cisplatin.27 BRCA1 expression confers dif-
ferential chemosensitivity in cell lines,28 and low levels of
FIGURE 1. Functional nucleotide excision repair (NER)
pathway and the repair of platinum damage. (A) Recogni-
tion of platinum adducts (shown as golden rings) by the
heterodimer XPC/hHR23B. (B) TFIIH contains two helicases,
which open an approximately 30-base-long DNA segment
around the damage. (C) This open intermediate is stabilized
by RPA and XPA. (D) The DNA strand that contains the
damaged base(s) is excised by XPG and excision repair
cross-complementing 1 (ERCC1)/XPF. XPG cleaves the dam-
aged DNA strand 3= from the lesion, and ERCC1/XPF cleaves
the damaged strand 5= from the lesion. (E) The resulting gap
is filled by DNA polymerase  or  in the presence of replica-
tion factors.
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BRCA1 correlated with increased survival in stage III
NSCLC patients treated with neoadjuvant cisplatin/gemcitab-
ine and then surgery.29
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